title: A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection.
abstract: Neutralizing antibody protection against HIV-1 may require broad and potent antibodies targeting multiple epitopes. We tested 7 monoclonal antibodies (MAbs) against 45 viruses of diverse subtypes from early infection. The CD4 binding site MAb NIH45-46W was most broad and potent (91% coverage; geometric mean 50% inhibitory concentration [IC(50)], 0.09 μg/ml). Combining NIH45-46W and a V3-specific MAb, PGT128, neutralized 96% of viruses, while PGT121, another V3-specific MAb, neutralized the remainder. Thus, 2 or 3 antibody specificities may prevent infection by most HIV-1 variants.
authors: Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors: Leslie
authors: L
authors: Goo
authors: Zahra
authors: Z
authors: Jalalian-Lechak
authors: Barbra A
authors: BA
authors: Richardson
authors: Julie
authors: J
authors: Overbaugh
mesh_terms: D000906:Antibodies / Q000737:chemistry; D000911:Antibodies, Monoclonal / Q000737:chemistry; D057134:Antibodies, Neutralizing; D000918:Antibody Specificity; D015704:CD4 Antigens / Q000096:biosynthesis; D016000:Cluster Analysis; D000939:Epitopes / Q000737:chemistry*; D015483:HIV Antibodies / Q000737:chemistry*; D015658:HIV Infections / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D020128:Inhibitory Concentration 50; D009500:Neutralization Tests; D011134:Polysaccharides / Q000737:chemistry
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D015704:CD4 Antigens; D000939:Epitopes; D015483:HIV Antibodies; D011134:Polysaccharides